Gilead Sciences, Inc. (GILD): Total Assets
$59.02B
As of 2025-12-31
$49.36B
As of 2026-06-30
-2.2%
3-year compound annual growth
-2.9%
5-year compound annual growth
+1.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.02B | 0.0% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $58.99B | -5.0% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $62.12B | -1.7% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $63.17B | -7.0% | 2024-02-23, Balance as of period end |
| 2021-12-31 | $67.95B | -0.7% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $68.41B | +11.0% | 2022-02-23, Balance as of period end |
| 2019-12-31 | $61.63B | -3.2% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $63.67B | -9.4% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $70.28B | +23.4% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $56.98B | +10.2% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $51.72B | +49.2% | 2017-02-27, Balance as of period end |
| 2014-12-31 | $34.66B | +53.5% | 2016-02-24, Balance as of period end |
| 2013-12-31 | $22.58B | +6.3% | 2015-02-25, Balance as of period end |
| 2012-12-31 | $21.24B | +22.8% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $17.30B | +49.3% | 2013-02-27, Balance as of period end |
| 2010-12-31 | $11.59B | +19.5% | 2012-02-23, Balance as of period end |
| 2009-12-31 | $9.70B | +39.8% | 2011-02-28, Balance as of period end |
| 2008-12-31 | $6.94B | n/a | 2010-03-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
Compare GILD, AMGN, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗